MedTrace Logo

Adressing PTSD Symptoms and Aggressive Behavior in Vulnerable Children in Burundi

NCT03498482 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2018-04-13

No results posted yet for this study

Summary

Children either living in the streets of Bujumbara or that are similarly affected by extreme poverty or violence are regularly exposed to traumatic events. Additionally, they often find themselves in situations where engaging in violent behavior appears to be useful or even necessary for survival. The Narrative Exposure Therapy for violent offenders (FORNET) aims to reduce both PTSD symptoms and aggressive behavior. It helps the children to anchor fearful experiences and potential positive emotions linked to violent behaviour in the past. Additionally, visions for the future are developed in order to enable reintegration into the family.

The investigators want to provide evidence, that FORNET effectively reduces PTSD symptoms and ongoing aggressive behavior which in change facilitates reintegration into society.

Conditions

Interventions

BEHAVIORAL

Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)

FORNET aims to reduce trauma-related symptoms and aggressive behavior via narrative exposure of traumatic and violent life events.

Sponsors & Collaborators

  • Vivo international e.V.

    collaborator INDUSTRY

  • Psychologues sans Frontières Burundi

    collaborator OTHER

  • Université Lumière de Bujumbura

    collaborator OTHER

  • University of Konstanz

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-15
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • Burundi

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03498482 on ClinicalTrials.gov